Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Melanoma, Nivolumab Ipilimumab Adjuvant

Reinhard Dummer

MD

🏢University Hospital Zurich🌐Switzerland

Professor, Head of Skin Cancer Center

69
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Reinhard Dummer has led multiple adjuvant and metastatic melanoma trials in Europe and contributed to defining the role of combination IO and BRAF/MEK inhibition in the adjuvant setting for high-risk resected melanoma. His work has explored long-term survival outcomes and quality of life in patients receiving adjuvant checkpoint inhibitor therapy. He has also contributed to research on uveal melanoma and rare melanoma subtypes.

Share:

🧪Research Fields 研究领域

adjuvant melanoma IO
nivolumab ipilimumab stage III melanoma
BRAF MEK adjuvant melanoma
metastatic uveal melanoma
melanoma response biomarkers

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Reinhard Dummer 的研究动态

Follow Reinhard Dummer's research updates

留下邮箱,当我们发布与 Reinhard Dummer(University Hospital Zurich)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment